Andre F, Grunenwald D, Pujol J L, Girard P, Dujon A, Brouchet L, Brichon P Y, Westeel V, Le Chevalier T
Department of Medicine, Gustave Roussy Institute, Villejuif, France.
Cancer. 2001 Jun 15;91(12):2394-400.
Although it induces a relevant reduction in the risk of both visceral metastases and locoregional recurrences, the combination of chemotherapy and surgery only marginally improves the survival of patients with Stage IIIA(N2) (International Union Against Cancer staging and classification system) nonsmall-cell lung carcinoma (NSCLC). The purpose of the current study was to analyze the patterns of relapse in these patients.
In this study, the authors compared the patterns of relapse in 81 patients with clinically detectable N2 NSCLC who had been treated with preoperative chemotherapy with the relapse patterns of 186 comparable patients who had been treated with primary surgery. Clinically detectable N2 (cN2) denotes mediastinal lymph node enlargement on computed tomography scan, which then is confirmed by mediastinoscopy.
Overall 20% of patients developed a locoregional recurrence. Chemotherapy decreased the risk of visceral metastasis as 28% of the patients preoperatively treated and 38%of those not treated with preoperative chemotherapy presented a visceral metastasis (P < 0.05). Preoperative chemotherapy and adenocarcinoma subtypes were associated with a higher rate of brain metastasis (P < 0.05). Thirty-two percent of the patients treated preoperatively and 18% of those not treated with preoperative chemotherapy presented a brain metastasis (P < 0.05), which was isolated in 22% and 11% of the patients, respectively (P < 0.05).
The current study found that preoperative chemotherapy for cN2 decreases the risk of visceral metastasis but is associated with a high rate of isolated brain metastases. Prophylactic cranial irradiation may need to be reinvestigated in clinical trials, especially in patients who present with an adenocarcinoma.
虽然化疗与手术联合应用能显著降低内脏转移和局部区域复发的风险,但对于ⅢA期(N2)(国际抗癌联盟分期和分类系统)非小细胞肺癌(NSCLC)患者,其生存获益仅略有改善。本研究旨在分析这些患者的复发模式。
在本研究中,作者比较了81例经术前化疗的临床可检测到N2的NSCLC患者与186例接受原发手术的类似患者的复发模式。临床可检测到的N2(cN2)是指计算机断层扫描显示纵隔淋巴结肿大,随后经纵隔镜检查证实。
总体上20%的患者出现局部区域复发。化疗降低了内脏转移风险,术前接受化疗的患者中有28%出现内脏转移,未接受术前化疗的患者中有38%出现内脏转移(P<0.05)。术前化疗和腺癌亚型与脑转移发生率较高相关(P<0.05)。术前接受治疗的患者中有32%出现脑转移,未接受术前化疗的患者中有18%出现脑转移(P<0.05),分别有22%和11%的患者为孤立性脑转移(P<0.05)。
本研究发现,cN2患者术前化疗可降低内脏转移风险,但与孤立性脑转移的高发生率相关。预防性颅脑照射可能需要在临床试验中重新研究,尤其是对于腺癌患者。